Tirzepatide and pregnancy

What the Tirzepatide label says about pregnancy

Both tirzepatide products — Zepbound and Mounjaro — direct you to discontinue when a pregnancy is recognized, on the basis of animal reproduction studies and insufficient human data. Neither is a formal contraindication.

One point worth being precise about, because most pages get it wrong: Tirzepatide is not a formal contraindication in pregnancy — that label wording is reserved for Saxenda. The instruction to stop sits in the pregnancy section rather than the contraindications list, which is a real distinction even though the practical advice is the same.

When to stop Tirzepatide before trying to conceive

The tirzepatide label gives no pre-pregnancy washout figure, unlike semaglutide’s labelled 2 months. Its roughly five-day half-life means about a month clears it — a pharmacology- and society-based number, not a labelled one.

What the warning is actually based on: animal data

Every warning on these labels comes from animal studies — rats and rabbits at clinically relevant doses showed embryo loss and structural abnormalities. Pregnant women were excluded from all the registration trials, so there is no human trial data behind the label caution.

What the human data show so far

The human evidence has started to arrive, and so far it is reassuring rather than alarming. A Danish nationwide cohort published in 2026 (756,636 pregnancies, 529 exposed to a GLP-1) found no increased risk of major malformations after matching. A 2024 registry study and a 2025 systematic review of over 1,000 semaglutide-exposed pregnancies reached the same conclusion. But these are observational, the numbers are small, they are weighted toward pregnancies with diabetes, and miscarriage is under-captured — so the honest read is "no red flag has emerged yet", not "proven safe".

What to do if you are already pregnant

If you find out you are pregnant while taking a GLP-1, the guidance from the labels, ACOG and the ADA is the same: stop the medication now and tell your prescriber. Inadvertent early exposure before you knew is not, on its own, a reason for any intervention beyond stopping and normal prenatal care — the human data on early exposure are reassuring. What matters next is managing the underlying condition without the drug.

Stopping the drug is not the end of the plan. Observational work in 2025 found that stopping a GLP-1 around pregnancy was linked to more gestational weight gain and higher rates of preterm birth, gestational diabetes and high blood pressure — not because stopping is wrong, but because the underlying metabolic condition still needs active management. Have that conversation with your clinician before you conceive, not after.

“Ozempic babies”: why unplanned pregnancies happen on these drugs

The unexpected-pregnancy stories are real, and there are two separate mechanisms behind them — and they are not the same across drugs.

• Restored ovulation. Weight loss and improved insulin sensitivity can restart ovulation in people who were not ovulating regularly — especially with PCOS. Fertility can return faster than expected, and it applies to every GLP-1. If you are not trying to conceive, this is the reason to keep contraception in place even if you were not before.
• The pill can fail — but only on tirzepatide. Tirzepatide contains tirzepatide, and its label warns that it can reduce the effectiveness of oral hormonal contraceptives by slowing stomach emptying. The advice is to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase. A single dose cut pill exposure by around a fifth to a half in the studies.

Breastfeeding

There is no human data on Tirzepatidein breast milk. The labels state this plainly and defer to a benefit-versus-risk judgement with your clinician rather than an outright ban. Clinicians often note that these are large peptide molecules, unlikely to pass into milk in quantity and likely to be broken down in an infant's gut — but that is pharmacologic reasoning, not human evidence, and the labels are clear that the data are simply absent.

For the cross-drug comparison and the full evidence, see GLP-1 and pregnancy.